Xbrane is hosting a Virtual Capital Markets Day on May 17th, 2021

Corporate Information

English

News

Presentation

Stockholm, Sweden – Xbrane (Nasdaq: XBRANE), a late-stage clinical biopharma company is inviting analysts, investors and media to the company’s Virtual Capital Markets Day on May 17th, 2021 at 14.00-15.30 CET.

The event will feature presentations from Xbrane’s Board and Management team outlining the company strategy and the next steps in the company's ambition to become a leading global biosimilar developer. The program will also include a virtual show of the recently established new development lab.

The event will start at 14.00 and will be broadcast live.

Please register using the following link;

https://tv.streamfabriken.com/xbrane-biopharma-cmd-2021

Xbrane Biopharma	Anders Tullgren, Chairman
The Biosimilar Market	Martin Åmark, CEO
Xlucane™	Martin Åmark, CEO
Platform Technology & Capabilities	David Vikström, Head of R&D
Virtual tour of the new Biotech lab	Siavash Bashiri, Deputy CEO
A world-leading Biosimilar Developer	Martin Åmark, CEO
Wrap-up and Q&A session	Martin Åmark, CEO

Agenda in brief:

Participants are invited to ask questions to IR@xbrane.com or live during the event.

Recordings of the presentations, and the presentations themselves, will be made available on the website www.xbrane.com.

About Us

Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane’s leading product Xlucane™, a Lucentis® biosimilar candidate, addresses the SEK 106 billions ophthalmic VEGFa inhibitor market. Xlucane™ is in phase III and filing of marketing authorization application is planned for the latter part of 2021. Xbrane has additionally three biosimilars in its pipeline targeting SEK 100 billions in originator sales. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE.
For more information, visit www.xbrane.com.